Antiretroviral potency of 4′-ethnyl-2′-fluoro-2′-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes | Zendy

Duncan Njenda | Zendy; Shambhu G. Aralaguppe | Zendy; Kamalendra Singh | Zendy; Rohit Rao | Zendy; Anders Sönnerborg | Zendy; Stefan G. Sarafianos | Zendy; Ujjwal Neogi | Zendy

Open Access

Antiretroviral potency of 4′-ethnyl-2′-fluoro-2′-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes

Author(s) -

Duncan Njenda,

Shambhu G. Aralaguppe,

Kamalendra Singh,

Rohit Rao,

Anders Sönnerborg,

Stefan G. Sarafianos,

Ujjwal Neogi

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky256

Subject(s) - efavirenz , etravirine , tenofovir alafenamide , rilpivirine , virology , nevirapine , reverse transcriptase , raltegravir , potency , human immunodeficiency virus (hiv) , reverse transcriptase inhibitor , chemistry , dolutegravir , deoxyadenosine , biology , dna , antiretroviral therapy , viral load , rna , biochemistry , in vitro , gene

4'-Ethnyl-2'-fluoro-2'-deoxyadenosine (EFdA) is a novel translocation-defective reverse transcriptase inhibitor. We investigated the virological and biochemical inhibitory potentials of EFdA against a broad spectrum of subtype-specific chimeric viruses and compared it with tenofovir alafenamide, nevirapine, efavirenz, rilpivirine and etravirine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research